425: Akari Therapeutics and Peak Bio Announce Merger of Equals, Expanding Pipeline with Novel ADC Toolkit

Akari Therapeutics and Peak Bio have entered into a definitive agreement to merge as equals in an all-stock transaction, creating an expanded pipeline with a novel antibody drug conjugate (ADC) toolkit.

Summary

• Akari Therapeutics and Peak Bio have announced a definitive agreement to merge in an all-stock transaction.
• The combined entity will operate as Akari Therapeutics, Plc and is expected to continue to be listed on the Nasdaq Capital Market under the ticker AKTX.
• The merger will result in an expanded pipeline featuring multiple assets in early and late development stages.
• Key highlights include Peak Bio's innovative ADC toolkit, Akaris nomacopan (Phase 3 for HSCT-TMA), Akaris long-acting nomacopan (pre-clinical for GA), and Peak Bios Phase 2-ready PHP-303 program (AATD).
• The merged company will emphasize business development and licensing.
• Hoyoung Huh, M.D., Ph.D., is expected to serve as the incoming Chairman of the Board.
• Peak stockholders will receive Akari ordinary shares (represented by American Depositary Shares) based on an exchange ratio, resulting in approximately 50% ownership for each company's shareholders on a fully-diluted basis.
• The transaction is expected to close late in the second quarter of this year, pending customary closing conditions and shareholder approvals.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting the expanded pipeline and potential benefits. However, it also acknowledges the inherent risks and uncertainties associated with forward-looking statements.

Positives

• The merger creates an expanded pipeline with assets in both early and late stages of development.
• Peak Bio's ADC toolkit adds a novel technology platform to Akaris portfolio.
• Akaris nomacopan has potential to be the first approved treatment for HSCT-TMA, a disease with high mortality.
• Long-acting nomacopan targets a significant unmet need in geographic atrophy (GA) treatment.
• The combined company will have a strategic focus on business development and licensing.
• The leadership team has extensive strategic and operational experience.

Risks

• The transaction is subject to customary closing conditions, including shareholder approvals, and may not be completed on the expected timeline or at all.
• The combined company may not realize the anticipated benefits of the merger.
• The transaction could affect relationships with employees, business partners, or governmental entities.
• The combined company faces risks related to research and development, regulatory approvals, competition, and market acceptance of its product candidates.
• The combined company may face unforeseen liabilities or unexpected costs.

Future Outlook

The combined company plans to assess the pipeline, prioritize programs, update timelines, and pursue near-term value creation opportunities, with a strategic emphasis on business development and licensing.

Management Comments

• Hoyoung Huh, M.D., Ph.D. is expected to serve as incoming Chairman of the Board of the combined entity.

Industry Context

The merger reflects a trend in the biotechnology industry towards consolidation and pipeline expansion to mitigate risk and enhance value creation. The focus on ADC technology aligns with the growing interest in targeted cancer therapies.

Comparison to Industry Standards

• The document mentions several companies with complement therapeutics, such as Alexion (acquired by AstraZeneca), Apellis, Astellas/Iveric, and UCB/Ra Pharma.
• Alexion's Soliris and Ultomiris are C5 inhibitors used for PNH, aHUS, gMG, and NMOSD.
• Apellis's Empaveli is a C3 inhibitor used for PNH, and Syfovre is used for GA.
• Astellas/Iveric's IZERVAY is a C5 inhibitor used for GA.
• UCB/Ra Pharma's zilucoplan is a C5 inhibitor in Phase 3 for gMG.
• The document positions Akaris nomacopan as a novel dual-action inhibitor of C5 and LTB4, potentially offering advantages over complement-only inhibitors.

Management Changes

Stakeholder Impact

• Shareholders of both Akari and Peak Bio will be impacted by the merger, with their ownership stakes converted into shares of the combined company.
• Employees of both companies may experience changes in their roles and responsibilities as a result of the integration.
• Patients may benefit from the development of new therapies for autoimmune, inflammatory, and oncology diseases.
• The merger could affect relationships with suppliers, distributors, and other business partners.

Next Steps

• Obtain shareholder approvals from both Akari and Peak Bio.
• Secure Nasdaq approval for listing the new Akari shares.
• Complete the PIPE Investment.
• Close the merger transaction, expected late in the second quarter of this year.
• Assess the combined pipeline and prioritize programs.
• Pursue business development and licensing opportunities.

Key Dates